Basic Information
| RNALocate ID: | RLID:11002755 |
| RNA Symbol: | hsa-miR-20b-5p |
| Localization: | Exosome |
RNA Information
| RNA Name: | hsa-miR-20b-5p |
| RNA ID: | miRBase:MIMAT0001413 |
| RNA Category: | miRNA |
| Species: | Homo sapiens |
Localization Information
| PubMed ID: | 22211110 |
| Tissue/Cell Line: | Breast milk |
| Method: | Next-generation RNA sequencing |
|
The expression profile of selected miRNAs in breast milk exosomes. Originally published in Int J Biol Sci. Zhou Q, et al, 2012. Reproduced under the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) |
|
| Description: | Distribution and characterization of miRNAs in breast milk exosomes. (A) Distribution of pre-miRNAs. Out of 1,424 pre-miRNAs deposited in miRBase 17.0 (blue circle), 87 (6.11%) pre-miRNAs have been designated as immune-related pre-miRNAs based on annotation in the Pathway Central database (SABiosciences, MD, USA). Immune-related pre-miRNAs (59 of 452, 13.05%) are enriched in breast milk exosomes (red circle). χ2 test: Number of immune-related miRNAs and others detected in breast milk exosomes compared with the total entries in miRBase 17.0. (B) Top ten most highly expressed unique miRNAs. Plot of the unique miRNAs (starting from the miRNA with the highest counts, x-axis) versus their cumulative % of the total counts from 602 unique miRNAs detected in breast milk exosomes for each small RNA library. Values are means ± s.d. The dashed horizontal line at 62.3% represents the level of the top ten unique miRNAs and the % of individual miRNAs is marked by the gray line. (C-E) The expression profile of selected miRNAs in breast milk exosomes. (C) 59 immune-related pre-miRNAs; (D) miR-17-92 cluster and paralogous clusters, and (E) ten well-characterized tissue-specific pre-miRNAs. Data are collected from Figure 2. |
Other Subcellular Localization
| RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
| RLID:01002278 | Cytoplasm | Nasopharyngeal carcinoma cells | 20498841 |
| RLID:01002279 | Cytoplasm | Neural progenitor cells | 21363885 |
| RLID:01002280 | Mitochondrion | Cell line (HEK-293) | 22984580 |
| RLID:01002281 | Nucleolus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:01002282 | Nucleus | Nasopharyngeal carcinoma cells | 20498841 |
| RLID:01002283 | Nucleus | Colon adenocarcinoma cells | 20864815 |
| RLID:11002753 | Exosome | Primary dendritic cells|T cell line (J77) | 21505438 |
| RLID:11002754 | Exosome | Ovarian follicular fluid | 22116803 |
| RLID:11002756 | Exosome | Brain tissue | 23382797 |
| RLID:11002757 | Exosome | Plasma | 23663360 |
| RLID:11002758 | Exosome | Human mast cell line (HMC-1) | 24009880 |
| RLID:11002759 | Microvesicle | Seminal plasma | 23539611 |
| RLID:11002760 | Microvesicle | Follicular fluid | 23666971 |
| RLID-D:11000138 | Exosome | Seminal fluid | |
| RLID-D:11000451 | Microvesicle | Fibroblasts|Mesenchymal stem cells |
ncRNA Disease Information
| Resource | RNA Symbol | Disease | Link |
| MNDR | hsa-miR-20b-5p | Multiple sclerosis chronic progressive | MNDR-E-MI-27920 |
| MNDR | hsa-miR-20b-5p | Oral squamous cell carcinoma | MNDR-E-MI-27921 |
| MNDR | hsa-miR-20b-5p | Large cell neuroendocrine cancer | MNDR-E-MI-27922 |
| MNDR | hsa-miR-20b-5p | Medulloblastoma | MNDR-E-MI-27923 |
| MNDR | hsa-miR-20b-5p | High-grade serous ovarian carcinoma | MNDR-E-MI-27924 |
| MNDR | hsa-miR-20b-5p | Uterine corpus endometrial carcinoma | MNDR-E-MI-27925 |
| MNDR | hsa-miR-20b-5p | Lymphoma | MNDR-E-MI-27926 |
| MNDR | hsa-miR-20b-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-27927 |
| MNDR | hsa-miR-20b-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-27928 |
| MNDR | hsa-miR-20b-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-27929 |
| MNDR | hsa-miR-20b-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-27930 |
| MNDR | hsa-miR-20b-5p | Her2-receptor positive breast cancer | MNDR-E-MI-27931 |
| MNDR | hsa-miR-20b-5p | Breast cancer luminal | MNDR-E-MI-27932 |
| MNDR | hsa-miR-20b-5p | Dermatomyositis | MNDR-E-MI-27933 |
| MNDR | hsa-miR-20b-5p | Prostate cancer | MNDR-E-MI-27934 |
| MNDR | hsa-miR-20b-5p | Gastric cancer | MNDR-E-MI-27935 |
| MNDR | hsa-miR-20b-5p | Alzheimer disease | MNDR-E-MI-27936 |
| MNDR | hsa-miR-20b-5p | Intracranial aneurysm | MNDR-E-MI-27937 |
| MNDR | hsa-miR-20b-5p | Bladder cancer | MNDR-E-MI-27938 |
| MNDR | hsa-miR-20b-5p | Esophageal carcinoma | MNDR-E-MI-27939 |
| MNDR | hsa-miR-20b-5p | Dysautonomia familial | MNDR-E-MI-27940 |
| MNDR | hsa-miR-20b-5p | Leukemia | MNDR-E-MI-27941 |
| MNDR | hsa-miR-20b-5p | Friedreich ataxia | MNDR-E-MI-27942 |
| MNDR | hsa-miR-20b-5p | Cardiovascular disease | MNDR-E-MI-27943 |
| MNDR | hsa-miR-20b-5p | Carotid stenosis | MNDR-E-MI-27944 |
| MNDR | hsa-miR-20b-5p | Lung cancer | MNDR-E-MI-27945 |
| MNDR | hsa-miR-20b-5p | Parkinson disease | MNDR-E-MI-27946 |
| MNDR | hsa-miR-20b-5p | Basal-like breast cancer | MNDR-E-MI-27947 |
| MNDR | hsa-miR-20b-5p | Thyroid cancer | MNDR-E-MI-27948 |
| MNDR | hsa-miR-20b-5p | Pancreatic cancer | MNDR-E-MI-27949 |
| MNDR | hsa-miR-20b-5p | Melanoma | MNDR-E-MI-27950 |
| MNDR | hsa-miR-20b-5p | Rectum adenocarcinoma | MNDR-E-MI-27951 |
| MNDR | hsa-miR-20b-5p | Nephroblastoma | MNDR-E-MI-27952 |
| MNDR | hsa-miR-20b-5p | Colon cancer | MNDR-E-MI-27953 |
| MNDR | hsa-miR-20b-5p | Ischemic attack transient | MNDR-E-MI-27954 |
| MNDR | hsa-miR-20b-5p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-27955 |
| MNDR | hsa-miR-20b-5p | Prostate adenocarcinoma | MNDR-E-MI-27956 |
| MNDR | hsa-miR-20b-5p | Kidney cancer | MNDR-E-MI-27957 |
| MNDR | hsa-miR-20b-5p | Carcinoma ductal breast | MNDR-E-MI-27958 |
| MNDR | hsa-miR-20b-5p | Glioblastoma | MNDR-E-MI-27959 |
| MNDR | hsa-miR-20b-5p | Astrocytoma | MNDR-E-MI-27960 |
| MNDR | hsa-miR-20b-5p | Glioma | MNDR-E-MI-27961 |
| MNDR | hsa-miR-20b-5p | Central nervous system lymphoma | MNDR-E-MI-27962 |
| MNDR | hsa-miR-20b-5p | Amyotrophic lateral sclerosis | MNDR-E-MI-27963 |
| MNDR | hsa-miR-20b-5p | Osteosarcoma | MNDR-E-MI-27964 |
| MNDR | hsa-miR-20b-5p | Liposarcoma | MNDR-E-MI-27965 |
| MNDR | hsa-miR-20b-5p | Liver cancer | MNDR-E-MI-27966 |
| MNDR | hsa-miR-20b-5p | Cervical adenocarcinoma | MNDR-E-MI-27967 |
| MNDR | hsa-miR-20b-5p | Gastric adenocarcinoma | MNDR-E-MI-27968 |
| MNDR | hsa-miR-20b-5p | Cervical squamous cell carcinoma | MNDR-E-MI-27969 |
| MNDR | hsa-miR-20b-5p | Lung squamous cell carcinoma | MNDR-E-MI-27970 |
| MNDR | hsa-miR-20b-5p | Non-small cell lung adenocarcinoma | MNDR-E-MI-27971 |
| MNDR | hsa-miR-20b-5p | Lung adenocarcinoma | MNDR-E-MI-27972 |
| MNDR | hsa-miR-20b-5p | Adrenocortical cancer | MNDR-E-MI-27973 |
| MNDR | hsa-miR-20b-5p | Thyroid carcinoma | MNDR-E-MI-27974 |
| MNDR | hsa-miR-20b-5p | Ovarian carcinoma | MNDR-E-MI-27975 |
| MNDR | hsa-miR-20b-5p | Myasthenia gravis | MNDR-E-MI-27976 |
| MNDR | hsa-miR-20b-5p | Myasthenia gravis autoimmune experimental | MNDR-E-MI-27977 |
| MNDR | hsa-miR-20b-5p | Carcinoma renal cell | MNDR-E-MI-27978 |
| MNDR | hsa-miR-20b-5p | Kidney renal papillary cell carcinoma | MNDR-E-MI-27979 |
| MNDR | hsa-miR-20b-5p | Clear cell renal cell carcinoma | MNDR-E-MI-27980 |
| MNDR | hsa-miR-20b-5p | Biliary tract cancer | MNDR-E-MI-27981 |
| MNDR | hsa-miR-20b-5p | Cholangiocarcinoma | MNDR-E-MI-27982 |
| MNDR | hsa-miR-20b-5p | Esophageal cancer | MNDR-E-MI-27983 |
| MNDR | hsa-miR-20b-5p | Lung small cell carcinoma | MNDR-E-MI-27984 |
| MNDR | hsa-miR-20b-5p | Synovial sarcoma | MNDR-E-MI-27985 |
| MNDR | hsa-miR-20b-5p | Testicular germ cell cancer | MNDR-E-MI-27986 |
| MNDR | hsa-miR-20b-5p | T acute lymphoblastic leukemia | MNDR-E-MI-27987 |
| MNDR | hsa-miR-20b-5p | Acute t cell leukemia | MNDR-E-MI-27988 |
| MNDR | hsa-miR-20b-5p | Heart failure | MNDR-E-MI-27989 |
| MNDR | hsa-miR-20b-5p | Breast invasive carcinoma | MNDR-E-MI-27990 |
| MNDR | hsa-miR-20b-5p | Hepatocellular carcinoma | MNDR-E-MI-27991 |
| MNDR | hsa-miR-20b-5p | B-cell lymphoma | MNDR-E-MI-27992 |
| MNDR | hsa-miR-20b-5p | T-cell leukemia | MNDR-E-MI-27993 |
| MNDR | hsa-miR-20b-5p | Malignant pleural mesothelioma | MNDR-E-MI-27994 |
| MNDR | hsa-miR-20b-5p | Neuroblastoma | MNDR-E-MI-27995 |
| MNDR | hsa-miR-20b-5p | Barrett's adenocarcinoma | MNDR-E-MI-27996 |
| MNDR | hsa-miR-20b-5p | Hodgkin lymphoma | MNDR-E-MI-27997 |
| MNDR | hsa-miR-20b-5p | Colorectal cancer | MNDR-E-MI-27998 |
| MNDR | hsa-miR-20b-5p | Nasopharynx carcinoma | MNDR-E-MI-27999 |
| MNDR | hsa-miR-20b-5p | Multiple myeloma | MNDR-E-MI-28000 |
| MNDR | hsa-miR-20b-5p | Esophageal squamous cell carcinoma | MNDR-E-MI-28001 |
| MNDR | hsa-miR-20b-5p | Uterine cervical neoplasms | MNDR-E-MI-28002 |
| MNDR | hsa-miR-20b-5p | Ependymoma | MNDR-E-MI-28003 |
| MNDR | hsa-miR-20b-5p | Nasopharyngeal cancer | MNDR-E-MI-28004 |
| MNDR | hsa-miR-20b-5p | Prostatic neoplasms | MNDR-E-MI-28005 |
| MNDR | hsa-miR-20b-5p | Pseudorabies | MNDR-E-MI-28006 |
| MNDR | hsa-miR-20b-5p | Subarachnoid hemorrhage traumatic | MNDR-E-MI-28007 |
| MNDR | hsa-miR-20b-5p | Gait ataxia | MNDR-E-MI-28008 |
| MNDR | hsa-miR-20b-5p | Stroke lacunar | MNDR-E-MI-28009 |
| MNDR | hsa-miR-20b-5p | Barrett's carcinogenesis | MNDR-E-MI-28010 |
RNA Interaction Information
| Resource | RNA Symbol | Species | Link | RNALocate ID |
| RNAInter | AC021078.1 | Homo sapiens | RR00029797 |
TOP